Alzheimer's disease, Alector

Alector’s AbbVie-Partnered Alzheimer’s Program Fails Phase II, Triggering a 17% Layoff
Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech expects its current cash position to last it through 2026.
UPDATED: Alector lays off 17% of staff after AbbVie-partnered Alzheimer's asset fails phase 2
Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a string of investigational meds missing the mark in the indication. | Alector’s Abbvie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study,
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is cut by 17%.
Alector Therapeutics’ novel Alzheimer’s strategy fails in Phase 2 trial
Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's disease. Its drug failed the Phase 2 trial.
Alector Plummets After Alzheimer's Drug Trial Fails Primary Endpoint
Alector said that, in addition to failure to meet the primary endpoint of the study, no treatment effects favored AL002 on secondary clinical and functional endpoints. The company said it had $457.2 million worth of cash,
Business Insider19h
Buy Rating Maintained for Alector Despite AL002 Setback, Focus on Promising AL001 and Strong Financials
Don't Miss our Black Friday Offers: Graig Suvannavejh’s rating is based on several strategic considerations despite the recent disappointing data for Alector’s AL002. Although the Phase 2 results ...
Yahoo Finance14h
Alector stock drops after Alzheimer’s drug fails in Phase II trial
Alector’s internal pipeline suffered a blow as the Phase II INVOKE-2 trial evaluating its Alzheimer’s disease therapy, ...
Morningstar20d
Alector Reports Third Quarter 2024 Financial Results and Provides Business Update
In October 2024, Alector published a manuscript titled “Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer’s disease” in Alzheimer’s ...
Business Insider21h
Alector Downgraded to Underweight After Disappointing AL002 Phase 2 Results
Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Jeffrey Hung has given his Sell rating due to a combination of factors, primarily driven by the unfavorable ...
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...